Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.

Gordon KB, Armstrong AW, Foley P, Song M, Shen YK, Li S, Muñoz-Elías EJ, Branigan P, Liu X, Reich K.

J Invest Dermatol. 2019 Dec;139(12):2437-2446.e1. doi: 10.1016/j.jid.2019.05.016. Epub 2019 Jun 15.

PMID:
31207232
2.

Correction: Nasopharyngeal Exposure to Streptococcus pneumoniae Induces Extended Age-Dependent Protection against Pulmonary Infection Mediated by Antibodies and CD138+ Cells.

Bou Ghanem EN, Maung NHT, Siwapornchai N, Goodwin AE, Clark S, Muñoz-Elías EJ, Camilli A, Gerstein RM, Leong JM.

J Immunol. 2018 Dec 1;201(11):3471. doi: 10.4049/jimmunol.1801354. Epub 2018 Oct 29. No abstract available.

3.

Nasopharyngeal Exposure to Streptococcus pneumoniae Induces Extended Age-Dependent Protection against Pulmonary Infection Mediated by Antibodies and CD138+ Cells.

Bou Ghanem EN, Maung NHT, Siwapornchai N, Goodwin AE, Clark S, Muñoz-Elías EJ, Camilli A, Gerstein RM, Leong JM.

J Immunol. 2018 Jun 1;200(11):3739-3751. doi: 10.4049/jimmunol.1701065. Epub 2018 Apr 16. Erratum in: J Immunol. 2018 Dec 1;201(11):3471.

4.

Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial.

Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, DePrimo SE, Muñoz-Elías EJ, Brodmerkel C, Dasgupta B, Chevrier M, Smith K, Horwinski J, Tyldsley A, Grice EA.

J Invest Dermatol. 2018 Sep;138(9):1973-1981. doi: 10.1016/j.jid.2018.03.1501. Epub 2018 Mar 17.

5.

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis.

Land J, Lintermans LL, Stegeman CA, Muñoz-Elías EJ, Tarcha EJ, Iadonato SP, Heeringa P, Rutgers A, Abdulahad WH.

Front Immunol. 2017 Sep 26;8:1205. doi: 10.3389/fimmu.2017.01205. eCollection 2017.

6.

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.

Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elías EJ, Kruger JG, Iadonato SP.

PLoS One. 2017 Jul 19;12(7):e0180762. doi: 10.1371/journal.pone.0180762. eCollection 2017.

7.

Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).

Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Muñoz-Elías EJ, Callis Duffin K.

Br J Dermatol. 2017 Dec;177(6):1552-1561. doi: 10.1111/bjd.15722. Epub 2017 Nov 16.

PMID:
28600818
8.

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.

Tarcha EJ, Chi V, Muñoz-Elías EJ, Bailey D, Londono LM, Upadhyay SK, Norton K, Banks A, Tjong I, Nguyen H, Hu X, Ruppert GW, Boley SE, Slauter R, Sams J, Knapp B, Kentala D, Hansen Z, Pennington MW, Beeton C, Chandy KG, Iadonato SP.

J Pharmacol Exp Ther. 2012 Sep;342(3):642-53. doi: 10.1124/jpet.112.191890. Epub 2012 May 25.

9.

Isolation of Streptococcus pneumoniae biofilm mutants and their characterization during nasopharyngeal colonization.

Muñoz-Elías EJ, Marcano J, Camilli A.

Infect Immun. 2008 Nov;76(11):5049-61. doi: 10.1128/IAI.00425-08. Epub 2008 Sep 15.

10.

Dual role of isocitrate lyase 1 in the glyoxylate and methylcitrate cycles in Mycobacterium tuberculosis.

Gould TA, van de Langemheen H, Muñoz-Elías EJ, McKinney JD, Sacchettini JC.

Mol Microbiol. 2006 Aug;61(4):940-7.

11.

Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence.

Muñoz-Elías EJ, Upton AM, Cherian J, McKinney JD.

Mol Microbiol. 2006 Jun;60(5):1109-22.

12.

Carbon metabolism of intracellular bacteria.

Muñoz-Elías EJ, McKinney JD.

Cell Microbiol. 2006 Jan;8(1):10-22. Review.

PMID:
16367862
13.

Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence.

Muñoz-Elías EJ, McKinney JD.

Nat Med. 2005 Jun;11(6):638-44. Epub 2005 May 15.

14.

Replication dynamics of Mycobacterium tuberculosis in chronically infected mice.

Muñoz-Elías EJ, Timm J, Botha T, Chan WT, Gomez JE, McKinney JD.

Infect Immun. 2005 Jan;73(1):546-51.

15.

Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.

McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR Jr, Russell DG.

Nature. 2000 Aug 17;406(6797):735-8.

PMID:
10963599
16.

VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines.

Delgado M, Munoz-Elias EJ, Martinez C, Gomariz RP, Ganea D.

Ann N Y Acad Sci. 1999;897:401-14. Review. No abstract available.

PMID:
10676466
17.

Functional characterization of the MODY1 gene mutations HNF4(R127W), HNF4(V255M), and HNF4(E276Q).

Navas MA, Munoz-Elias EJ, Kim J, Shih D, Stoffel M.

Diabetes. 1999 Jul;48(7):1459-65.

PMID:
10389854
18.

VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells.

Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D.

J Neuroimmunol. 1999 May 3;96(2):167-81.

PMID:
10337915

Supplemental Content

Loading ...
Support Center